FDA OKs Amvuttra To Treat Heart Conditions
ATTR-CM is a disease in which harmful proteins build up in the heart, making it harder to pump blood, according to the ...
Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock
CM, expanding its market reach. JP Morgan upgrades the stock, projecting strong sales and a multi-billion opportunity.
PMLive12h
Alnylam’s Amvuttra granted FDA approval for rare heart disease ATTR-CM
Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the Food and Drug Administration (FDA) to treat ...
Zacks.com on MSN10h
Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains?
Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...
Trump elevates Susan Monarez as nominee for CDC director
President Trump selected Susan Monarez, the acting director of the Centers for Disease Control and Prevention, for the ...
Alnylam upgraded to Overweight from Neutral at JPMorgan
JPMorgan upgraded Alnylam (ALNY) to Overweight from Neutral with a price target of $328, up from $280. The firm increased TTR silencer ...
Royal Bank of Canada Increases Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $330.00
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective lifted by Royal Bank of Canada from $310.00 to ...
Natixis Advisors LLC Boosts Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Natixis Advisors LLC grew its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 4.5% during the 4th quarter, HoldingsChannel reports. The fund owned 10,453 shares of ...
Managed Healthcare Executive10h
Novo Nordisk Extends Lowered Wegovy Price to Retail Pharmacies
Wegovy is also available through NovoCare Pharmacy, which directly ship all dose strengths at a cost of $499 per month for ...